Hanahan revisits the evolving framework of cancer hallmarks, synthesizing 25 years of conceptual refinement into a multidimensional view of tumor biology. This review highlights how aberrant capabilit...

A binding-to-release drug conjugate strategy enables targeted payload release without cellular internalization, improving tumour specificity, efficacy and expanding therapeutic targets beyond conventi...

On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combi...

Gudauskaitė et al. show that the mechanism driving oncogenic protein overexpression influences the effectiveness of targeted protein degradation. While stabilizing mutations do not limit protein deple...

The FDA is responsible for protecting and promoting the public health

The U.S. Food and Drug Administration today issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr) as the first-ever treatment for adults and children 8 years of age and older ...

Temporal protein-abundance measurements from systematically perturbed breast cancer cell lines were generated to develop ProteinTalks, a virtual cell model that functions as an operational tool for di...

Deliver the greatest possible impact to people through mRNA medicines.

Behera et al. characterize spatial biology patterns across 262 solid tumors and 18 tumor types, using spatial transcriptomics and multiplexed immunofluorescence. They find pan-tumor, hierarchically or...

On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who ...

The FDA is responsible for protecting and promoting the public health

The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced, ref...

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

Circadian timing of antigen exposure programs CD8+ T cell memory and tunes antiviral immunity.

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. ...

Chemotherapy, particularly with platinum-based drugs, is associated with substantial, rapidly detectable mutagenesis in childhood cancers, tripling private signatures and doubling mutation burden, hig...

Abstract. Pancreatic ductal adenocarcinoma (PDAC) arises from precursor lesions over a decade-plus, offering a window for interception in high-risk individuals, but current surveillance detects a mino...